Meanwhile, its combination with durvalumab aims to exploit the immunomodulatory effects of ATR inhibition, such as enhanced tumor immunogenicity and increased T-cell infiltration, as previously shown in DDR-deficient tumors. Here, ATR is linked to neoplasm.